Finally, we proved that ABCG1 was acting as a downstream molecule of the CCN2-LRP6-Wnt/β-catenin signaling pathway in HCC, and IP6 treatment resulted in the downregulation of ABCG1 and inhibition of CCN2-LRP6-Wnt/β-catenin signaling, while ABCG1 was not the only target of IP6 treatment on HCC cells. This evidence concerns the gene CCN2 and hepatocellular carcinoma.